Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - topiramate -

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - topiramate -

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - topiramate -

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - topiramate, quantity: 100 mg - tablet - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium starch glycollate type a; pregelatinised maize starch; magnesium stearate; titanium dioxide; hypromellose; polysorbate 80; iron oxide yellow; macrogol 400 - 1. epilepsy. rbx topiramate tablets are indicated in adults and children, 2 years and over:. - as monotherapy in patients with newly diagnosed epilepsy. - for conversion to monotherapy in patients with epilepsy. - as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome.. 2. migraine. rbx topiramate tablets are indicated for the prophylaxis of migraine headache in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - topiramate, quantity: 25 mg - tablet - excipient ingredients: pregelatinised maize starch; sodium starch glycollate type a; magnesium stearate; microcrystalline cellulose; lactose monohydrate; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - 1. epilepsy. rbx topiramate tablets are indicated in adults and children, 2 years and over:. - as monotherapy in patients with newly diagnosed epilepsy. - for conversion to monotherapy in patients with epilepsy. - as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome.. 2. migraine. rbx topiramate tablets are indicated for the prophylaxis of migraine headache in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - topiramate -

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - topiramate -

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - topiramate, quantity: 25 mg - tablet, film coated - excipient ingredients: magnesium stearate; sodium starch glycollate; microcrystalline cellulose; pregelatinised maize starch; lactose monohydrate; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - epilepsy: topiramate is indicated in adults and children 2 years and over: ? as monotherapy in patients with newly diagnosed epilepsy ? for conversion to monotherapy in patients with epilepsy ? as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome.,migraine: topiramate is indicated for the prophylaxis of migraine headache in adults.

United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - topiramate (unii: 0h73wjj391) (topiramate - unii:0h73wjj391) - topiramate 25 mg - topiramate tablets and topiramate capsules are indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older. topiramate tablets and topiramate capsules are indicated as adjunctive therapy for the treatment of partial-onset seizures,  primary generalized tonic-clonic seizures, and seizures associated with lennox-gastaut syndrome in patients 2 years of age and older. topiramate tablets and topiramate capsules are indicated for the preventive treatment of migraine in patients 12 years of age and older. none. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to topiramate during pregnancy. patients should be encouraged to enroll in the north american antiepileptic drug (naaed) pregnancy registry if they become pregnant. this registry is collecting information about the safety of antiepileptic drugs during pregnancy. to enroll, patients can call the toll-free n

United States - English - NLM (National Library of Medicine)

state of florida doh central pharmacy - topiramate (unii: 0h73wjj391) (topiramate - unii:0h73wjj391) - topiramate 25 mg - topiramate tablets, usp and topiramate capsules (sprinkle) are indicated as initial monotherapy in patients 2 years of age and older with partial onset or primary generalized tonic-clonic seizures. safety and effectiveness in patients who were converted to monotherapy from a previous regimen of other anticonvulsant drugs have not been established in controlled trials [see clinical studies (14.1) ]. topiramate tablets, usp and topiramate capsules (sprinkle) are indicated as adjunctive therapy for adults and pediatric patients ages 2 to 16 years with partial onset seizures or primary generalized tonic-clonic seizures, and in patients 2 years of age and older with seizures associated with lennox-gastaut syndrome [see clinical studies (14.2) ]. none. pregnancy category d . [see warnings and precautions (5.7)]   topiramate can cause fetal harm when administered to a pregnant woman. data from pregnancy registries indicate that infants exposed to topiramate in utero have an increased risk for cleft lip and/or cleft